Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
GlobeAlert Desk · curated from South China Morning Post · East Asia
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
What the desk knows about this story
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Single-source so far. Treat details as unconfirmed until more publishers report.
Not flagged as developing.
- Nvidia ceo jensen huangs future uncertain as megaspeed pledges to cooperate with us probeAttacks & Assaults · China · 13h ago
- Long March 12 | SatNet LEO Group TBD?Rocket Launches · CHN · now
- Long March 8A | SatNet LEO Group TBD?Rocket Launches · CHN · now